^
Association details:
| Biomarker: | CD19 underexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Zynlonta (loncastuximab tesirine-lpyl) (DNA replication inhibitor, CD19-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4297 CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling
Published date:
11/03/2022
Excerpt:
CD19 expression determined by immunohistochemistry (IHC) was evaluated in a cohort of patients…Responses to Lonca were seen in patients across all levels of CD19 expression, including patients with extremely low or no detectable CD19 expression at baseline and extremely low H-Scores....Response to Lonca was observed in R/R DLBCL patients with very low CD19 tumor expression as measured by IHC.
DOI:
https://doi.org/10.1182/blood-2022-159626
Trial ID:
